Ocean Biomedical, a small biotechnology company based in Rhode Island, will go public through a SPAC merger Aesther Healthcare Acquisition Corp, which is deviating from plans to list shares through a traditional IPO.
Ocean Biomedical focuses on oncology, infectious diseases and fibrosis. The company filed for an IPO in June 2021, initially expecting to offer shares in between $14 to $17, which would equate to $45 to $54 million in funding. However, over time, Ocean has revised down its target range and number of shares on offer. Show approval applications.
Ocean, however, is no exception. Many biotechs have struggled in their attempts to go public. Only 5 biotech companies rated IPOs in the second quarter of 2022, compared to 30 in the second quarter of 2021. And of those companies that have gone public, most have since lost value market trade.
SPACs, or Special Purpose Acquisition Companies, offer an alternative to IPOs and give companies another route to IPOs. While SPAC deals have been around for a long time, they’ve gained significant traction in the tech and biotech industries in recent years.
However, that trend appears to be slowing as some biotech SPACs have underperformed. Additionally, SPACs fell under in 2021 test of shareholders and the Securities and Exchange Commission
The merger between Ocean and Aesther is expected to close in the fourth quarter of this year, with the new company holding an enterprise value of $345 million. The company name is “Ocean Biomedical, Inc.” and shares are listed on the Nasdaq as “OCEA” and “OCEAW”.
Comments are closed.